Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Samsung BioLogics
Pharma
Takeda, AZ-Daiichi, Fosun-Henlius—Fierce Pharma Asia
Takeda's R&D chief explained his new investment priorities. AZ and Daiichi's TROP2 ADC cleared the FDA. Fosun failed to buy out Henlius. And more.
Angus Liu
Jan 24, 2025 8:55am
Sales up 23% for Korean CDMO powerhouse Samsung Biologics
Jan 22, 2025 11:41am
Simcere, Takeda and Samsung Biologics—Fierce Pharma Asia
Jan 17, 2025 10:58am
JPM25: CDMO giant Samsung Bio weighs plan to build 6th plant
Jan 15, 2025 9:46am
China cuts, CSL site closure and Kyowa deal—Fierce Pharma Asia
Nov 22, 2024 3:00am
Samsung Bio strikes $668M production tie-up with European pharma
Nov 20, 2024 2:02pm